Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will conduct a webcast and conference call on July 12, 2022, at 8:00 a.m. ET to present top-line results from a crossover clinical trial of reproxalap, an investigational treatment for dry eye disease. The event will be accessible via dial-in or through a live audio webcast on Aldeyra's website. The trial aims to provide insights on the efficacy of reproxalap, which is in late-stage trials targeting immune-mediated diseases. Further details and archives will be available on their website.

Positive

• Conducting a conference call to report top-line results indicates confidence in trial outcomes.
• Reproxalap is aimed at treating a prevalent condition, potentially expanding Aldeyra's market presence.

Negative

• None.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report top-line results from the crossover clinical trial of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease.

The dial-in numbers are (844) 200-6205 for domestic callers and (646) 904-5544 for international callers. The access code is 853619. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra

Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005532/en/

Investor & Media:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: (857) 383-2409

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What is the purpose of Aldeyra's webcast on July 12, 2022?

The webcast will report top-line results from a crossover clinical trial of reproxalap for dry eye disease.

What is reproxalap being tested for?

Reproxalap is an investigational drug candidate intended for the treatment of dry eye disease.

How can I access the Aldeyra conference call?

Participants can dial in using local numbers or access the live audio webcast on Aldeyra's investor website.

What are the next steps following the trial results announcement?

Next steps will depend on the reported outcomes, potentially including further clinical development or regulatory submissions.

What is the significance of Aldeyra's investigational drug reproxalap?

Reproxalap aims to address a significant unmet need in the treatment of dry eye disease, which could enhance Aldeyra's portfolio.